Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma

International Journal of Cancer

Volumn 73, Issue 6, 1997, Pages 891-896

  Jansen, Willy J M ^a   Kolfschoten, Geertruida M ^a   Erkelens, Caroline A M ^a   Van Ark Otte, Jannette ^a   Pinedo, Herbert M ^a   Boven, Epie ^a,b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; IRINOTECAN; MESSENGER RNA;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; DRUG SCREENING; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOUSE; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RNA, MESSENGER; SARCOMA; SARCOMA, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 0031564110     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971210)73:6<891::AID-IJC22>3.0.CO;2-6     Document Type: Article

References (24)

1. ABIGERGES, D., CHABOT, G.G., ARMAND, J.P., HERAIT, P., GOUYETTE, A. and GANDIA, D., Phase-1 and pharmacologie studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J. clin. Oncol., 13, 210-221 (1995).
2. ARMAND, J.P., EXTRA, Y.M., CATIMEL, G., ABIGERGES, D., MARTY, M. and CLAVEL, M., Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase-II studies, as determined by European phase-I studies. Ann. Oncol., 7, 837-842 (1996).
3. BISSERY, M.C., VRIGNAUD, P., LAVELLE, F. and CHABOT, G.G., Experimental anti-tumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11 ) in mice. Anti-Cancer Drugs, 7, 437-460 (1996).
4. BOVEN, E., CALAME, J.J., MOLTHOFF, C.F.M. and PINEDO, H.M., Characterization and chemotherapy of human soft-tissue-sarcoma (STS) lines grown in nude mice. Strahlenther. Onkol., 165, 538-539 (1989).
5. BOVEN, E., WINOGRAD, B., BERGER, D.P., DUMONT, M.P., BRAAKHUIS, B.J.M., FODSTAD, O., LANGDON, S. and FIEBIG, H.H., Phase-II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res., 52, 5940-5947 (1992).
6. BURKE, T.G. and MI, Z., The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. med. Chem., 37, 40-46 (1994).
7. DANCEY, J. and EISENHAUER, E.A., Current perspectives on camptothecins in cancer treatment. Brit. J. Cancer, 74, 327-338 (1996).
8. EISENHAUER, E.A., WAINMAN, N., BOOS, G., MACDONALD, D. and BRAMWELL, V., Phase-II trials of topotecan in patients with malignant glioma and soft-tissue sarcoma. Proc. Amer. Soc. clin. Oncol., 13, 488 (1994).
9. GIACCONE, G., VAN ARK-OTTE, J., SCAGLIOTTI, G., CAPRANICO, G., VAN DER VALK, P., RUBIO, G., DALESIO, O., LOPEZ, R., ZUNINO, F., WALBOOMERS, J. and PINEDO, H.M., Differential expression of DNA topoisomerases in non-small-cell lung cancer and normal lung. Biochim. biophys. Acta, 1264, 337-346 (1995).
10. GOLDWASSER, F., BAE, I., VALENTI, M., TORRES, K. and POMMIER, Y., Topoisomerase-I-related parameters and camptothecin activity in the colon-carcinoma cell lines from the National Cancer Institute anti-cancer screen. Cancer Res., 55, 2116-2121 (1995).
11. GUPTA, E., LESTINGI, T.M., MICK, R., RAMIREZ, J., VOKES, E.E. and RATAIN, M.J., Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54, 3723-3725 (1994).
12. HARE, C.B., ELION, G.B., HOUGHTON, P.J., HOUGHTON, J.A., KEIR, S., MARCELLI, S.L., BIGNER, D.D. and FRIEDMAN, H.S., Therapeutic efficacy of the topoisomerase-I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin against pediatric and adult central-nervous-system-tumor xenografts. Cancer Chemother. Pharmacol., 39, 187-191 (1997).
13. HOUGHTON, P.J., CHESHIRE, P.J., HALLMAN, J.D., LUTZ, L., FRIEDMAN, H.S., DANKS, M.K. and HOUGHTON, J.A., Efficacy of topoisomerase-I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36, 393-403 (1995).
14. JANSEN, W.J.M., ZWART, B., HULSCHER, T.M., GIACCONE, G., PINEDO, H.M. and BOVEN, E., CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int. J. Cancer, 70, 335-340 (1997).
15. KAWATO, Y., FURUTA, T., AONUMA, M., YASUOKA, M., YOKOKURA, T. and MATSUMOTO, K., Anti-tumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28, 192-198 (1991).
16. KUNIMOTO, T. NITTA, K., TANAKA, T., UEHARA, N., BABA, H., TAKEUCHI, M., YOKOKURA, T., SAWADA, S., MIYASAKA, T. and MUTAI, M., Anti-tumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, u novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47, 5944-5947 (1987).
17. LANGDON, S.P., HENDRIKS, H.R., BRAAKHUIS, B.J.M., PRATESI, G., BERGER, D.P., FODSTAD, O., FIEBIG, H.H. and BOVEN, E., Preclinical phase-II studies in human tumor xenografts: a European multicenter follow-up study. Ann. Oncol., 5, 415-422 (1994).
18. LOKIEC, F., MONEGIER DU SORBIER, B. and SANDERINK, G.J., Irinotecan (CPT-11) metabolites in human bile and urine. Clin. Cancer Res., 2, 1943-1949 (1996).
19. MI, Z. and BURKE, T.G., Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry, 33, 12540-12545 (1994).
20. MOLTHOFF, C.F.M., CALAME, J.J., PINEDO, H.M. and BOVEN, E., Human ovarian-cancer xenografts in nude mice: characterization and analysis of antigen expression. Int. J. Cancer, 47, 72-79 (1991).
21. NARITA, M., NAGAI, E., HAGIWARA, H., ABURADA, M., YOKOI, T. and KAMATAKI, T., Inhibition of β-glucuronidase by natural glucuronides of Kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica, 23, 5-10 (1993).
22. NIWA, K., MISAO, R., HANABAYASHI, T., MORISHITA, S., MURASE, T., ITOH, M., ITOH, N., MORI, H. and TAMAYA, T., Semi-quantitative analysis of DNA topoisomerase-I mRNA level using reverse-transcription-polymerase chain reaction in cancer cell lines: its relation to cytotoxicity against camptothecin derivative. Jap. J. Cancer Res., 85, 869-874 (1994).
23. TAKASUNA, K., HAGIWARA, T., HIROHASHI, M., KATO, M., NOMURA, M., NAGAI, E., YOKOI, T. and KAMATAKI, T., Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the anti-tumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res., 56, 3752-3757 (1996).
24. TAKEUCHI, S., TAKAMIZAWA, H., TAKEDA, Y., OKAWA, T., TAMAYA, T., NODA, K., SUGAWA, K., SEKIBA, K., YAKUSHIJI, M. and TAGUCHI, T., Clinical study of CPT-11, camptothecin derivative, on gynecological malignancy. Proc. Amer. Soc. clin. Oncol., 10, 189 (1991).